Do muscle-preservation supplements actually work on GLP-1s?

No supplement has been tested for muscle preservation in people taking GLP-1 medications. As of August 2026, zero completed trials exist; the first began recruiting in May 2026. Resistance training and adequate protein are the evidence-backed answers. Creatine monohydrate has strong lean-mass evidence in older adults — but only alongside resistance training. Collagen, omega-3 and vitamin D are weaker.

People on semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and liraglutide do lose real lean mass — roughly a quarter of total weight lost in the cleanest DEXA data (PMID 39996356). The supplement market responded to that before the science did.

Here is the size of the gap. The first trial to test a supplement for lean mass in this population — creatine alongside resistance training — began recruiting in May 2026 (NCT07625202, n=40) and is not due to report until 2027. A second, HMB with vitamin D (NCT07760948), has not begun. Until they report, every ingredient claim in this category — mine included — is extrapolated from a different population. And the one published RCT that combined tirzepatide with resistance training was retracted in 2025. If you have seen it cited, that is why it is not cited here. Nothing on the first page of results for this question mentions the retraction. Why GLP-1 weight loss can cause new joint pain covers the joint side of the same problem.

What actually preserves lean mass

Before any table of ingredients, the two things with decades of trial evidence behind them: resistance training and eating enough protein.

The anchor study is Longland 2016. In a 40% energy deficit with intense exercise, participants eating 2.4 g/kg/day of protein gained 1.2 kg of lean mass; those eating 1.2 g/kg/day did not (PMID 26817506). Read that honestly — young men, four weeks, not GLP-1 users. The principle is well established; those exact numbers were not derived in this population.

Energy deficiency blunts how much lean mass training can add, but not the strength you gain from it (PMID 28630601). Training still works while you are losing weight. Protein spread across meals matters more than one large dose, and that matters more with age, as the amount of leucine needed to trigger muscle protein synthesis rises.

The only human data in actual GLP-1 users is a three-patient case series: resistance training three to five times a week with 1.6–2.3 g/kg fat-free mass of protein preserved or increased lean soft tissue in two of three patients despite 27–33% bodyweight loss (PMID 41122508). Two of three. The third still lost lean mass. That is the entire evidence base in this population.

The verdict table

Grades describe the strength of evidence for this use — preserving lean mass or easing joint pain during GLP-1 weight loss. Strong: multiple meta-analyses, consistent direction, relevant population. Moderate: meta-analytic support, small or borderline effect. Mixed: best evidence in the closest population is non-significant. Weak: plausible mechanism, human evidence thin by its own authors' assessment. Not supported for this use: no trial evidence for this outcome.

The Verdict column is our editorial judgement, labelled as such. The Evidence column is not — every claim in it carries a PMID you can check. And one grade applies to every row: none of it has been tested in GLP-1 users.

Creatine, in detail

Creatine earns the strongest grade in this table, with one condition attached that most marketing leaves out.

A 22-RCT meta-analysis in 721 older adults (mean age 57–70) found creatine during resistance training added 1.37 kg of lean tissue mass alongside chest-press and leg-press strength gains (PMID 29138605). In postmenopausal women — the closest demographic match to this audience — a 2026 meta-analysis of 7 RCTs found +0.37 kg lean mass and +7.5 kg leg-press one-rep max (PMID 42141930).

The condition: that benefit required at least 5 g/day combined with resistance training. At 3 g/day or less without training, there was no effect. Creatine works by increasing phosphocreatine availability for high-intensity effort. If that effort is not happening, there is nothing for it to act on.

Practically: 3–5 g/day of creatine monohydrate is the studied form, and a loading phase is not required. The water retention people worry about is intracellular — it is inside muscle, not fat. There is no known interaction with semaglutide or tirzepatide; creatine is not cleared through the CYP450 pathways that drive most drug interactions. And every trial above was in people who were lifting, and none was in anyone taking a GLP-1.

Protein powder, and the nausea problem

Protein has the strongest evidence of anything here and the worst adherence on these medications, for an obvious reason: the drugs suppress appetite, and shakes often make nausea worse. This is the most under-served practical problem for this audience and almost nobody writing about it addresses it.

What tends to help: splitting protein across several smaller meals rather than one large shake; whole-food sources many people tolerate better — Greek yogurt, cottage cheese, eggs, fish; serving colder and more dilute. That is practical guidance rather than trial-derived, and it is labelled as such. The actual g/kg targets belong with the training protocol, not on a supplement page.

The weak tier: collagen, omega-3, vitamin D

Three ingredients sold hard to this audience whose evidence does not match the marketing.

Collagen is genuinely positive for muscle performance (SMD 0.60) and bone-turnover markers (PMID 41049371) — but most of the positive data comes from studies where it was given alongside calcium and vitamin D, and the joint-pain claim it is usually sold on is thinner than the muscle and bone-marker data.

Omega-3 has a plausible mechanism for anabolic resistance, and its own reviewers describe the human evidence as limited by small sample sizes and heterogeneity (PMID 37504930). Benefit is suggested above 2 g/day. Suggested is the right word.

Vitamin D is the hard null, and it is the one a supplement company has the clearest incentive to bury. In 29 RCTs in postmenopausal women — again, the closest demographic match available — handgrip strength did not reach statistical significance (p=0.06) and mobility showed nothing at all (p=0.76) (PMID 31729817). Benefit appeared only in people who were deficient to begin with. Correcting a measured deficiency is a legitimate clinical action. Taking vitamin D as a muscle supplement when your level is normal is not supported.

Why we left CBD out of our own formula

Reclaim Labs has sold CBD since it started. I have had rheumatoid arthritis for 23 years and came off long-term prednisone; CBD is the category I built this company in.

When we designed the Mobility Complex formula, putting CBD in it was the obvious commercial move. Existing supply chain, existing customers, a ready-made story.

We left it out. There is no trial evidence that CBD preserves lean mass in any population, and the best meta-analysis of CBD on inflammatory markers — 13 RCTs — described the effects as inconsistent and trivial (PMID 41373770). CBD may have a place elsewhere in our catalogue for other reasons. It does not have one here.

So what should you actually do

1. Resistance training, two to three sessions a week. Non-negotiable, and the thing every supplement above depends on to work at all.
2. Hit a protein target. Spread across meals, food first.
3. If you are already training, creatine monohydrate at 3–5 g/day is the one supplement with a strong evidence base in populations adjacent to yours.
4. Test vitamin D before supplementing it, not after.
5. Track function, not only the scale. In SEMALEAN, handgrip strength improved by 4.5 kg even as lean mass fell (PMID 41068996). Stairs, grip and carrying capacity tell you more than a DEXA number alone. The honest caveat: longer-term data in older adults with type 2 diabetes does show reduced handgrip and accelerated sarcopenia with prolonged semaglutide use, so that reassurance is short-term rather than permanent.

We are developing Reclaim Mobility Complex, a joint and muscle support formula for people on GLP-1 medications, targeting Q4 2026. It has not been studied. It is not a substitute for training or protein. If you want to hear when it exists — including if the evidence turns against it — the waitlist is here.

Common questions